Sex differences in the therapeutic effects of anti-PDL2 neutralizing antibody on stroke

Hilary A. Seifert, Wenbin Zhu, Arthur Vandenbark, Nabil Alkayed, Halina Offner

Research output: Contribution to journalArticle

Abstract

Inflammation involving migration of immune cells across the damaged blood–brain barrier (BBB), activation of resident innate microglia and production of inflammatory humoral mediators such as cytokines and chemokines play a critical role in the pathogenesis of ischemic stroke. Cell-cell signaling involved in the process also includes checkpoint interaction between programmed death receptor (PD1) and programmed death ligands, PDL1 and PDL2. Based on our previous studies showing reduced MCAO infarct volumes in PDL2 deficient mice, we evaluated the ability of anti-PDL2 mAb to treat MCAO in male and female C57BL/6 mice. We found that anti-PDL2 neutralizing antibody treatment of MCAO significantly reduced infarct volumes in male mice but had no protective effects in female mice even at a 5-fold increased dose of anti-PDL2 mAb. The protection in male mice was likely mediated by reduced percentages in the spleen of PDL2+CD19+ B cells, PDL1+CD4+ T cells and CD86+CD11b+ macrophages in concert with reduced expression of PDL1 and TNFα and continued expression of CD206, in the injured ipsilateral brain hemisphere. The lack of a therapeutic benefit of anti-PDL2 on stroke-induced infarct volumes in female mice was reflected by no detectable reduction in expressed PDL2 or PDL1 and an increased frequency of Th1 and Th17 pro-inflammatory T cell subsets in the spleen, an effect not seen in PDL2 mAb treated males. This result potentially limits the utility of anti-PDL2 mAb therapy in stroke to males but underscores the importance of meeting the STAIR requirements for development of new stroke therapies for both sexes.

Original languageEnglish (US)
JournalMetabolic brain disease
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

T-cells
Therapeutic Uses
Neutralizing Antibodies
Sex Characteristics
Stroke
Cell signaling
Death Domain Receptors
Macrophages
Chemokines
Brain
Chemical activation
Cells
Cytokines
Ligands
Spleen
Microglia
T-Lymphocyte Subsets
Inbred C57BL Mouse
Cell Movement
B-Lymphocytes

Keywords

  • Anti-PDL2 mAb
  • Checkpoint regulation
  • MCAO
  • Sex differences

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

@article{3af01b99e18b460a90a4eea3ca73a3de,
title = "Sex differences in the therapeutic effects of anti-PDL2 neutralizing antibody on stroke",
abstract = "Inflammation involving migration of immune cells across the damaged blood–brain barrier (BBB), activation of resident innate microglia and production of inflammatory humoral mediators such as cytokines and chemokines play a critical role in the pathogenesis of ischemic stroke. Cell-cell signaling involved in the process also includes checkpoint interaction between programmed death receptor (PD1) and programmed death ligands, PDL1 and PDL2. Based on our previous studies showing reduced MCAO infarct volumes in PDL2 deficient mice, we evaluated the ability of anti-PDL2 mAb to treat MCAO in male and female C57BL/6 mice. We found that anti-PDL2 neutralizing antibody treatment of MCAO significantly reduced infarct volumes in male mice but had no protective effects in female mice even at a 5-fold increased dose of anti-PDL2 mAb. The protection in male mice was likely mediated by reduced percentages in the spleen of PDL2+CD19+ B cells, PDL1+CD4+ T cells and CD86+CD11b+ macrophages in concert with reduced expression of PDL1 and TNFα and continued expression of CD206, in the injured ipsilateral brain hemisphere. The lack of a therapeutic benefit of anti-PDL2 on stroke-induced infarct volumes in female mice was reflected by no detectable reduction in expressed PDL2 or PDL1 and an increased frequency of Th1 and Th17 pro-inflammatory T cell subsets in the spleen, an effect not seen in PDL2 mAb treated males. This result potentially limits the utility of anti-PDL2 mAb therapy in stroke to males but underscores the importance of meeting the STAIR requirements for development of new stroke therapies for both sexes.",
keywords = "Anti-PDL2 mAb, Checkpoint regulation, MCAO, Sex differences",
author = "Seifert, {Hilary A.} and Wenbin Zhu and Arthur Vandenbark and Nabil Alkayed and Halina Offner",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s11011-019-00476-3",
language = "English (US)",
journal = "Metabolic Brain Disease",
issn = "0885-7490",
publisher = "Springer New York",

}

TY - JOUR

T1 - Sex differences in the therapeutic effects of anti-PDL2 neutralizing antibody on stroke

AU - Seifert, Hilary A.

AU - Zhu, Wenbin

AU - Vandenbark, Arthur

AU - Alkayed, Nabil

AU - Offner, Halina

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Inflammation involving migration of immune cells across the damaged blood–brain barrier (BBB), activation of resident innate microglia and production of inflammatory humoral mediators such as cytokines and chemokines play a critical role in the pathogenesis of ischemic stroke. Cell-cell signaling involved in the process also includes checkpoint interaction between programmed death receptor (PD1) and programmed death ligands, PDL1 and PDL2. Based on our previous studies showing reduced MCAO infarct volumes in PDL2 deficient mice, we evaluated the ability of anti-PDL2 mAb to treat MCAO in male and female C57BL/6 mice. We found that anti-PDL2 neutralizing antibody treatment of MCAO significantly reduced infarct volumes in male mice but had no protective effects in female mice even at a 5-fold increased dose of anti-PDL2 mAb. The protection in male mice was likely mediated by reduced percentages in the spleen of PDL2+CD19+ B cells, PDL1+CD4+ T cells and CD86+CD11b+ macrophages in concert with reduced expression of PDL1 and TNFα and continued expression of CD206, in the injured ipsilateral brain hemisphere. The lack of a therapeutic benefit of anti-PDL2 on stroke-induced infarct volumes in female mice was reflected by no detectable reduction in expressed PDL2 or PDL1 and an increased frequency of Th1 and Th17 pro-inflammatory T cell subsets in the spleen, an effect not seen in PDL2 mAb treated males. This result potentially limits the utility of anti-PDL2 mAb therapy in stroke to males but underscores the importance of meeting the STAIR requirements for development of new stroke therapies for both sexes.

AB - Inflammation involving migration of immune cells across the damaged blood–brain barrier (BBB), activation of resident innate microglia and production of inflammatory humoral mediators such as cytokines and chemokines play a critical role in the pathogenesis of ischemic stroke. Cell-cell signaling involved in the process also includes checkpoint interaction between programmed death receptor (PD1) and programmed death ligands, PDL1 and PDL2. Based on our previous studies showing reduced MCAO infarct volumes in PDL2 deficient mice, we evaluated the ability of anti-PDL2 mAb to treat MCAO in male and female C57BL/6 mice. We found that anti-PDL2 neutralizing antibody treatment of MCAO significantly reduced infarct volumes in male mice but had no protective effects in female mice even at a 5-fold increased dose of anti-PDL2 mAb. The protection in male mice was likely mediated by reduced percentages in the spleen of PDL2+CD19+ B cells, PDL1+CD4+ T cells and CD86+CD11b+ macrophages in concert with reduced expression of PDL1 and TNFα and continued expression of CD206, in the injured ipsilateral brain hemisphere. The lack of a therapeutic benefit of anti-PDL2 on stroke-induced infarct volumes in female mice was reflected by no detectable reduction in expressed PDL2 or PDL1 and an increased frequency of Th1 and Th17 pro-inflammatory T cell subsets in the spleen, an effect not seen in PDL2 mAb treated males. This result potentially limits the utility of anti-PDL2 mAb therapy in stroke to males but underscores the importance of meeting the STAIR requirements for development of new stroke therapies for both sexes.

KW - Anti-PDL2 mAb

KW - Checkpoint regulation

KW - MCAO

KW - Sex differences

UR - http://www.scopus.com/inward/record.url?scp=85070679360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070679360&partnerID=8YFLogxK

U2 - 10.1007/s11011-019-00476-3

DO - 10.1007/s11011-019-00476-3

M3 - Article

JO - Metabolic Brain Disease

JF - Metabolic Brain Disease

SN - 0885-7490

ER -